Literature DB >> 28608276

A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases.

Andrea Cercek1, Vyacheslav Gendel2, Salma Jabbour3,4, Dirk Moore5, Chunxia Chen5, John Nosher2,3, Marinela Capanu6, Joanne F Chou6, Taryn Boucher1, Nancy Kemeny1, Darren R Carpizo7,8.   

Abstract

OPINION STATEMENT: Patients with unresectable hepatic colorectal metastases who become chemo-refractory have limited treatment options. Systemic chemotherapies such as TAS102 and regorafenib have been used in the refractory setting, but with only modest improvement in overall survival compared to best supportive care. In patients with liver-only or liver-dominant disease, direct chemotherapy to the liver such as hepatic artery infusional (HAI) chemotherapy and radioembolization (yttrium-90 (Y90)) should be considered. Due to the difficulty of HAI therapy post Y90 for technical reasons, we recommend HAI therapy prior to Y90.

Entities:  

Keywords:  Hepatic arterial infusion; Metastatic colorectal cancer; Refractory; Survival; Yttrium-90 microsphere radioembolization

Mesh：

Substances：

Year:  2017        PMID： 28608276     DOI： 10.1007/s11864-017-0481-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  33 in total

1.  Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.

Authors:  N Kemeny; M Gonen; D Sullivan; L Schwartz; F Benedetti; L Saltz; J Stockman; Y Fong; W Jarnagin; J Bertino; W Tong; P Paty
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Authors:  Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

3.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

4.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 5.  Yttrium-90 microspheres: radiation therapy for unresectable liver cancer.

Authors:  Riad Salem; Kenneth G Thurston; Brian I Carr; James E Goin; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2002-09       Impact factor: 3.464

6.  A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.

Authors:  N Kemeny; K Seiter; D Niedzwiecki; D Chapman; E Sigurdson; A Cohen; J Botet; P Oderman; P Murray
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

7.  Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.

Authors:  Nancy E Kemeny; Fidel D Huitzil Melendez; Marinela Capanu; Philip B Paty; Yuman Fong; Lawrence H Schwartz; William R Jarnagin; Dina Patel; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

8.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.

Authors:  N Kemeny; J Daly; B Reichman; N Geller; J Botet; P Oderman
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

Authors:  Sabine Tejpar; Sebastian Stintzing; Fortunato Ciardiello; Josep Tabernero; Eric Van Cutsem; Frank Beier; Regina Esser; Heinz-Josef Lenz; Volker Heinemann
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.